相关实验视频
Updated: Sep 10, 2025

Antigenic Liposomes for Generation of Disease-specific Antibodies
Published on: October 25, 2018
抗原导向的mRNA细胞疗法对B细胞成熟反应的持续时间
Nizar Chahin1, Gregory Sahagian2, Marc H Feinberg3
1Department of Neurology, Oregon Health and Sciences University, Portland, Oregon, USA.
一种针对BCMA的RNA仿真抗原受体T细胞疗法Descartes-08在肌痛性硬化症患者中显示出显著的改善. 大多数患者在12个月后保持好处,重复治疗对复发有效.
科学领域:
- 免疫学
- 神经学
- 细胞治疗
背景情况:
- 肌痛性肌痛症 (MG) 是一种自身免疫性疾病,其特征是针对神经肌肉结合的自身抗体.
- 耐火性通用MG存在重大未满足的医疗需求,现有疗法往往无法充分应对.
研究的目的:
- 评估DCARTES-08的12个月的结果,这是一种BCMA导向的RNA仿真抗原受体T细胞 (rCAR- T) 疗法,用于耐火性一般化肌痛症患者.
- 在第二阶段临床试验中评估Descartes-08的安全性和有效性.
主要方法:
- 一个2a期临床试验 (NCT04146051) 给出了Descartes-08在没有淋巴衰竭化疗的情况下的门诊患者.
- 七名参与者每周输注6次Descartes-08,在2,3,6,9和12个月后进行后续评估.
主要成果:
- 在第3个月,所有7名参与者均显示出MG严重程度的临床显著改善,没有显著的毒性.
- 在所有参与者中,明显的改善持续到第9个月;五个参与者在12个月内维持了反应.
- 在复发的参与者中,重新治疗是有效的,临床改善迅速且持续.
结论:
- 在治疗耐火性一般化肌痛性肌痛症方面,Descartes-08显示出有前途的疗效和耐受性.
- 以BCMA为向的rCAR- T疗法具有超出MG的抗体介导自身免疫性疾病的潜力.
更多相关视频
08:38Overcoming Unresponsiveness in Experimental Autoimmune Encephalomyelitis EAE Resistant Mouse Strains by Adoptive Transfer and Antigenic Challenge
Published on: April 9, 2012
10:32Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells
Published on: June 5, 2015
相关概念视频
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
Myasthenia Gravis: Diagnostic Tests
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
B Cell Activation and Differentiation
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
Cells of the Adaptive Immune Response
Satellite Stem Cells and Muscular Dystrophy
Cell-mediated Immune Responses